The Live Cell Encapsulation market is anticipated to reach USD 306.11 Million by 2030 at 3.60% CAGR during the forecast period 2022-2030.
Live Cell Encapsulation Market OverviewThe Live Cell Encapsulation market is anticipated to reach USD 306.11 Million by 2030 at 3.60% CAGR during the forecast period 2022-2030.The market is driven by factors like the rise in both public and private sector investments in supporting product development. The growing rate of research and development activities to improve the clinical efficacy of cell encapsulation technologies is raising the market's demand. The increased rate of public awareness related to the clinical role of encapsulated cells for disease management is accelerating the market. Furthermore, increasing research programs are conducted for the encapsulation process boosting the market growth. The awareness programs to improve the role of live-cell encapsulation in treating chronic diseases such as autoimmune diseases, cancers, etc., are enhancing its demand. Live cell encapsulation has become a promising technology in treating neurological disorders because the drugs encapsulated overcome the blood-brain barrier. Another disorder, type 1 diabetes, can be controlled by microencapsulation. Here the immune system will destroy the beta islet cells of the pancreas. Therefore, the insulin-producing cells are encapsulated to let the immune system not destroy them. It lets the encapsulated cells respond to the glucose levels by insulin production. The encapsulated cell can treat many diseases; due to this, its development is progressing. This is simultaneously driving the live-cell encapsulation market at the global level. The cost price of raw materials and substitutes for this method, such as alternative therapies, is restraining the market's growth. But the industrial player's development will save the market from the restricting factor in the forecast period.
The Live Cell Encapsulation Market has been segmented into manufacturing technique, polymer type, and application. The market, based on manufacturing technique, has been segmented into simple dripping, electrostatic dripping, coaxial airflow, rotating disk atomization, and others. The market, by polymer type, has been further segmented into alginate, HEMA-MMA, Chitosan, silica, cellulose sulfate, PAN-PVC, and others. The market, by application, has been segmented into drug delivery, regenerative medicine, cell transplantation, and others. The drug delivery segment is expected to hold a major share owing to the increasing use of live cell encapsulation techniques in drug delivery systems. The segment of regenerative medicine is expected to be the fastest growing segment due to the rising trend and benefits of encapsulation in the tissue engineering field.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The live cell encapsulation market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The live cell encapsulation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Balchem Corporation, Evonik Industries, Merck KGaA, BÜCHI Labortechnik AG, Lycored, Blacktrace Holdings Ltd., Living Cell Technologies, Reed Pacific Pty Limited, MiKroCaps, Biotime, Inc., Neurotech Holdings, LLC, Sernova Corporation, Encapsys, LLC, Sigilon Therapeutics, Inc., and Viacyte, Inc. are some of the key players in the global live cell encapsulation market.
Regional Market Summary
Geographically, the Americas is expected to dominate the global live cell encapsulation market due to the increasing per capita healthcare expenditure, and the heavy adoption of new technology.
Furthermore, rising expenses in research and development by healthcare bodies and the government is anticipated to drive the growth of the market in this region. Apart from this, increasing applications of regenerative medicine in the US is expecting to push the growth of live cell encapsulation market. For instance, According to the National Institutes of Health (NIH), approximately 5,00,000 Americans benefit from a transplant each year.
Europe showed a considerable amount of growth in the global live cell encapsulation market. The market growth in this region is because of the presence of a well-established healthcare system and increase in chronic diseases. For instance, according to cancer research UK, there were approximately 9, 921 cases of cancer diagnosed in 2015. Such high rates of cancer are likely to increase demand for the use of next-generation sequencing as well as increase the market demands for monoclonal bodies and cellular research. These factors are expected to have a positive impact on the live cell encapsulation market.
Asia-Pacific is expected to have a sturdy growth rate during the forecast period owing to the huge patient pool of chronic diseases and government initiatives of healthcare reforms. However, less capital investment is restricting the market growth of this region.
On the other hand, the Middle East & Africa has the least share of the market due to the low disposable income. Moreover, the limited adoption of advanced healthcare facilities and limited access to treatment facilities is also expected to drive the growth of the market in the near future.
Global Live Cell Encapsulation Market, by Manufacturing Technique
Global Live Cell Encapsulation Market, by Application
Global Live Cell Encapsulation Market, by Region
In April 2022
PharmaCyte Biotech, Inc. a global biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology.
Cell-in-a-Box announced the management team would be attending the 15th International Conference on Advanced Technologies and Treating Diabetes (ATTD) held on April 27-30, 2022, in Barcelona, Spain. It is a scientific conference established in 2008. Intended Audience
Live cell encapsulation market was valued at USD 306.11 Million in 2030.
The global market is expected to exhibit a steady 3.60% CAGR over the forecast period from 2022 to 2030.
Growing awareness about the possibility of using encapsulated cells to treat various chronic diseases is the major driver for the global cell encapsulation market.
Difficulties in acquiring high-quality raw materials and changes in regulatory policies are the major restraints on the live cell encapsulation market.
Leading players in the live cell encapsulation market include Balchem Corporation, Sernova Corporation, Blacktrace Holdings Ltd., Merck, Neurotech Holdings LLC, Living Cell Technologies, MiKroCaps, and Biotime Inc., among others.